Nimvastid (Rivastigmine)

Rivastigmine, the active ingredient in Nimvastid, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It treats mild to moderate Alzheimer’s disease and Parkinson’s disease dementia in adults.

GNH USA supplies Nimvastid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rivastigmine acts on the cholinergic pathway to improve cognition in neurodegenerative conditions.

- Alzheimer’s disease (mild to moderate): helps maintain memory, attention and daily functioning. - Parkinson’s disease dementia: supports cognitive abilities and reduces confusion. - Vascular dementia (off‑label in some regions): may provide modest cognitive benefit.

Rivastigmine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Loss of appetite - Weight loss - Dizziness

Serious or Rare Side Effects: - Severe vomiting or gastrointestinal bleeding - Bradycardia or syncope - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hepatic enzyme elevations - Respiratory difficulties - Allergic anaphylaxis

Before initiating therapy, clinicians should consider several safety aspects.

- Dose titration: start low and increase gradually as tolerated. - Cardiovascular monitoring: observe for bradycardia or syncope, especially in patients with pre‑existing heart disease. - Gastrointestinal monitoring: watch for persistent nausea, vomiting, or signs of bleeding. - Renal/hepatic impairment: assess function and adjust if necessary. - Drug interactions: review concomitant medications for cholinergic or anticholinergic effects. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Rivastigmine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticholinergic agents: may diminish therapeutic effect. - Beta‑blockers: can exacerbate bradycardia. - Other acetylcholinesterase inhibitors: risk of excess cholinergic activity.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may increase nausea. - Antihypertensives: potential additive hypotensive effect. - Warfarin: monitor INR for possible changes.